GSK stock has experienced significant movements and trends recently, crossing above its 200-day moving average, signaling a potential turning point. The company continues share buybacks with over 4 billion voting shares in issue and buys 500,000 shares under the ongoing buyback program. With strong performance across specialty medicines boosting full-year outlook, GSK is eyeing $55 billion in sales, irrespective of obesity treatments. Major strongholds like Morgan Stanley and JPMorgan maintain an underweight rating, while Shore Capital Group offers a buy rating. GSK shares surged by 31% in 2025 amidst vaccine breakthroughs while the company exchanges a $2.2 billion buyout with Rapt Therapeutics and reporting a surge in HIV and cancer drug sales, lifting their 2025 outlook. Meanwhile, the company's respiratory and immunology pipeline will be boosted with a $2.2 billion RAPT buyout. Lastly, GSK has added 96,525 shares to LSE listing under employee share programs, guaranteeing stakeholder value.
GSK Stocks News Analytics from Fri, 01 Aug 2025 07:00:00 GMT to Fri, 27 Mar 2026 11:43:56 GMT - Innovation 6 - Rumor 7
